Research analysts at Leerink Partners began coverage on shares of Palvella Therapeutics (NASDAQ:PVLA – Get Free Report) in a report released on Monday, MarketBeat.com reports. The firm set an “outperform” rating and a $228.00 price target on the stock. Leerink Partners‘s price objective points to a potential upside of 57.95% from the stock’s current price.
Several other research firms also recently issued reports on PVLA. Weiss Ratings restated a “sell (d-)” rating on shares of Palvella Therapeutics in a report on Friday, September 25th. Oppenheimer upped their price objective on shares of Palvella Therapeutics from $210.00 to $232.00 and gave the company an “outperform” rating in a research report on Friday, November 6th. Chardan Capital reiterated a “buy” rating and issued a $240.00 target price on shares of Palvella Therapeutics in a research note on Wednesday, October 28th. William Blair started coverage on Palvella Therapeutics in a research report on Friday, October 16th. They set an “outperform” rating on the stock. Finally, Canaccord Genuity Group boosted their price target on Palvella Therapeutics from $232.00 to $243.00 and gave the company a “buy” rating in a research note on Monday, November 9th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Palvella Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $214.86.
Get Our Latest Research Report on Palvella Therapeutics
Palvella Therapeutics Stock Performance
Palvella Therapeutics (NASDAQ:PVLA – Get Free Report) last released its earnings results on Thursday, November 5th. The company reported ($1.70) EPS for the quarter, beating the consensus estimate of ($1.78) by $0.08. Equities analysts forecast that Palvella Therapeutics will post -6.29 earnings per share for the current year.
Insider Buying and Selling at Palvella Therapeutics
In other Palvella Therapeutics news, Director Christopher Kiritsy sold 313 shares of the business’s stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $157.00, for a total value of $49,141.00. Following the sale, the director owned 250 shares of the company’s stock, valued at $39,250. The trade was a 55.60% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Jeffrey S. Martini sold 6,250 shares of the stock in a transaction on Tuesday, November 10th. The shares were sold at an average price of $166.98, for a total transaction of $1,043,625.00. Following the completion of the transaction, the insider owned 4,266 shares of the company’s stock, valued at approximately $712,336.68. This represents a 59.43% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 63,004 shares of company stock worth $9,145,763 over the last three months. 17.20% of the stock is currently owned by corporate insiders.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Bank of America Corp DE boosted its stake in Palvella Therapeutics by 25.4% in the 1st quarter. Bank of America Corp DE now owns 37,972 shares of the company’s stock valued at $4,733,000 after buying an additional 7,700 shares in the last quarter. The Manufacturers Life Insurance Company raised its stake in Palvella Therapeutics by 688.9% during the first quarter. The Manufacturers Life Insurance Company now owns 17,907 shares of the company’s stock worth $2,232,000 after acquiring an additional 15,637 shares in the last quarter. Blue Owl Capital Holdings LP acquired a new position in Palvella Therapeutics during the second quarter worth $5,541,000. Deutsche Bank AG acquired a new position in Palvella Therapeutics during the second quarter worth $1,809,000. Finally, WCM Investment Management LLC bought a new position in shares of Palvella Therapeutics during the first quarter valued at $4,982,000. Institutional investors own 40.11% of the company’s stock.
About Palvella Therapeutics
Palvella Therapeutics is a clinical-stage biopharmaceutical company developing treatments for patients with rare and serious diseases, with a focus on conditions affecting the skin and related tissues. The company is based in Wayne, Pennsylvania. Its pipeline includes QTORIN-based topical drug candidates, which use the company’s platform to deliver medicines locally to affected tissue. Programs are being developed for conditions including microcystic lymphatic malformations and cutaneous venous malformations; these candidates are investigational and have not been established as approved treatments.
Further Reading
- Five stocks we like better than Palvella Therapeutics
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Palvella Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palvella Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
